hydroxychloroquine has been researched along with Deficiency, Vitamin D in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vitamin D deficiency was frequent in Chinese SLE patients and was associated with more active disease at baseline and over time, as well as a trend of more severe lupus flares." | 1.48 | Serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus: a longitudinal cohort analysis. ( Bro, ET; Ho, LY; Jannetto, PJ; Mok, CC; Singh, RJ, 2018) |
| "Vitamin D deficiency is highly prevalent in patients with SLE." | 1.43 | Severe vitamin D deficiency increases the risk for moderate to severe disease activity in Chinese patients with SLE. ( Gao, CC; Gao, GM; Li, TF; Liu, SY; Liu, ZS; Wu, ZZ; Zheng, ZH, 2016) |
| "Fatigue was quantified using a 0-10 visual analogue scale (VAS)." | 1.35 | Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. ( Aguirre, C; Egurbide, MV; Martinez-Berriotxoa, A; Olivares, N; Ruiz-Irastorza, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Stroehlein, JK | 1 |
| Wallqvist, J | 1 |
| Iannizzi, C | 1 |
| Mikolajewska, A | 1 |
| Metzendorf, MI | 1 |
| Benstoem, C | 1 |
| Meybohm, P | 1 |
| Becker, M | 1 |
| Skoetz, N | 1 |
| Stegemann, M | 1 |
| Piechotta, V | 1 |
| Mok, CC | 1 |
| Bro, ET | 1 |
| Ho, LY | 1 |
| Singh, RJ | 1 |
| Jannetto, PJ | 1 |
| Fangtham, M | 1 |
| Petri, M | 1 |
| Angelakis, E | 1 |
| Oddoze, C | 1 |
| Raoult, D | 1 |
| Gao, CC | 1 |
| Liu, SY | 1 |
| Wu, ZZ | 1 |
| Li, TF | 1 |
| Gao, GM | 1 |
| Liu, ZS | 1 |
| Zheng, ZH | 1 |
| Ruiz-Irastorza, G | 1 |
| Egurbide, MV | 1 |
| Olivares, N | 1 |
| Martinez-Berriotxoa, A | 1 |
| Aguirre, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)[NCT04366908] | Phase 2 | 517 participants (Actual) | Interventional | 2020-05-07 | Completed | ||
| Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial[NCT04449718] | 240 participants (Actual) | Interventional | 2020-06-01 | Completed | |||
| Short Term, High Dose Vitamin D Supplementation for COVID-19 Disease: Double Blind, Controlled, Study[NCT04459247] | 40 participants (Actual) | Interventional | 2020-06-15 | Completed | |||
| Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone[NCT03187743] | 72 participants (Actual) | Interventional | 2018-04-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxychloroquine and Deficiency, Vitamin D
| Article | Year |
|---|---|
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
2013 update: Hopkins lupus cohort.
Topics: Antirheumatic Agents; Cardiovascular Diseases; Cognition Disorders; Cohort Studies; Creatinine; Gluc | 2013 |
4 other studies available for hydroxychloroquine and Deficiency, Vitamin D
| Article | Year |
|---|---|
Serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus: a longitudinal cohort analysis.
Topics: Adult; Calcifediol; Female; Humans; Hydroxychloroquine; Longitudinal Studies; Lupus Erythematosus, S | 2018 |
Vitamin D and prolonged treatment with photosensitivity-associated antibiotics.
Topics: Adult; Aged; Anti-Bacterial Agents; Doxycycline; Endocarditis; Female; Humans; Hydroxychloroquine; M | 2013 |
Severe vitamin D deficiency increases the risk for moderate to severe disease activity in Chinese patients with SLE.
Topics: Adult; Calcifediol; China; Cross-Sectional Studies; Female; Humans; Hydroxychloroquine; Lupus Erythe | 2016 |
Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences.
Topics: Adult; Age Factors; Antirheumatic Agents; Calcifediol; Cross-Sectional Studies; Fatigue; Female; Hum | 2008 |